146 related articles for article (PubMed ID: 8868372)
1. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
2. Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists.
Maj J; Rogóz Z; Skuza G; Jaros T
Pol J Pharmacol; 1995; 47(4):269-77. PubMed ID: 8616504
[TBL] [Abstract][Full Text] [Related]
3. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
Donevan SD; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
[TBL] [Abstract][Full Text] [Related]
4. Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex.
Dereń-Wesołek A; Maj J
Pol J Pharmacol; 1993; 45(5-6):467-80. PubMed ID: 7912135
[TBL] [Abstract][Full Text] [Related]
5. Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice.
Maj J; Rogóz Z; Skuza G
Pol J Pharmacol; 1993; 45(4):349-60. PubMed ID: 7906989
[TBL] [Abstract][Full Text] [Related]
6. Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.
Borowicz KK; Duda AM; Kleinrok Z; Czuczwar SJ
Pol J Pharmacol; 2001; 53(2):101-8. PubMed ID: 11787948
[TBL] [Abstract][Full Text] [Related]
7. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Hauber W; Waldenmeier MT
Eur J Pharmacol; 1994 May; 256(3):339-42. PubMed ID: 7913894
[TBL] [Abstract][Full Text] [Related]
8. Disruption of operant oral self-administration of ethanol, sucrose, and saccharin by the AMPA/kainate antagonist, NBQX, but not the AMPA antagonist, GYKI 52466.
Stephens DN; Brown G
Alcohol Clin Exp Res; 1999 Dec; 23(12):1914-20. PubMed ID: 10630610
[TBL] [Abstract][Full Text] [Related]
9. Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7- dichloro-kynurenic acid, glycine site antagonists.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1994; 46(3):115-24. PubMed ID: 8000442
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of AMPA-type glutamate receptor antagonists on intermale social behavior in two mouse lines bidirectionally selected for offensive aggression.
Vekovischeva OY; Aitta-aho T; Verbitskaya E; Sandnabba K; Korpi ER
Pharmacol Biochem Behav; 2007; 87(2):241-9. PubMed ID: 17537494
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
Skuza G; Rogóz Z; Wieczorek A
Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
[TBL] [Abstract][Full Text] [Related]
12. Protection against non-NMDA receptor-mediated excitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat.
Kovács AD; Egyed A
Neurobiology (Bp); 1996; 4(1-2):59-72. PubMed ID: 9116695
[TBL] [Abstract][Full Text] [Related]
13. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
14. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
15. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test.
Maj J; Rogóz Z; Skuza G; Sowińska H
Pol J Pharmacol Pharm; 1992; 44(4):337-46. PubMed ID: 1363131
[TBL] [Abstract][Full Text] [Related]
16. Riluzole, a glutamate release inhibitor, and motor behavior.
Kretschmer BD; Kratzer U; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):181-90. PubMed ID: 9750003
[TBL] [Abstract][Full Text] [Related]
17. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
18. Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling.
Weiczner R; Krisztin-Péva B; Mihály A
Epilepsy Res; 2008 Jan; 78(1):22-32. PubMed ID: 18036781
[TBL] [Abstract][Full Text] [Related]
19. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
20. Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine.
O'Hearn E; Molliver ME
Neuroscience; 2004; 127(2):373-83. PubMed ID: 15262328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
